MONTREAL, QUEBEC -- (MARKET WIRE) -- March 01, 2007 -- Theratechnologies (TSX: TH) announced today that top-line results from its TH9507 Phase 3 clinical trial in patients with HIV-associated lipodystrophy were presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI) in Los Angeles, California on February 26, 2007. The presentation (which can be viewed in its entirety through the Internet at www.retroconference.org) was made by Dr. Steve Grinspoon, Associate Professor of Medicine, Harvard Medical School and lead investigator for the TH9507 trial in the United States. Preliminary data from the study were first released on December 19, 2006.
